Grifols, S.A. (NASDAQ:GRFS) Given Average Rating of “Hold” by Brokerages

Shares of Grifols, S.A. (NASDAQ:GRFS) have been assigned an average recommendation of “Hold” from the five brokerages that are presently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $10.00.

Several research analysts have recently issued reports on GRFS shares. Wall Street Zen raised Grifols from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Zacks Research upgraded shares of Grifols from a “strong sell” rating to a “hold” rating in a research report on Friday, February 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Grifols in a research report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. cut their price objective on Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a research report on Monday, December 8th.

Grifols Price Performance

Shares of GRFS opened at $9.22 on Friday. Grifols has a twelve month low of $6.19 and a twelve month high of $11.14. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.93 and a current ratio of 2.48. The firm’s 50-day moving average is $9.13 and its two-hundred day moving average is $9.46.

Institutional Trading of Grifols

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc lifted its holdings in Grifols by 39.5% in the 3rd quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,584 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Grifols by 25.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 1,212 shares during the last quarter. Peterson Wealth Services lifted its stake in shares of Grifols by 385.8% during the third quarter. Peterson Wealth Services now owns 7,287 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 5,787 shares during the period. Allworth Financial LP lifted its stake in shares of Grifols by 15.7% during the fourth quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 1,096 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in Grifols by 127.4% during the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 4,604 shares during the last quarter.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.